Perceptions of Patients with Primary Nonadherence to Statin Medications

References

1. 1.↵
   1. Mozaffarian D,
   2. Benjamin EJ,
   3. Go AS,
   4. et al

   . Heart disease and stroke statistics—2016. Update: a report from the American Heart Association. Circulation 2016;133:e38–e360.

   OpenUrlFREE Full Text
2. 2.↵
   1. Lloyd-Jones DM,
   2. Hong Y,
   3. Labarthe D,
   4. et al

   . Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic impact goal through 2020 and beyond. Circulation 2010;121:586–613.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Grundy SM,
   2. Stone NJ,
   3. Bailey AL,
   4. et al

   . AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;139:e1082–e1143.

   OpenUrl
4. 4.↵
   1. Grundy SM,
   2. Stone NJ,
   3. Bailey AL,
   4. et al

   . AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;139:e1046–e1081.

   OpenUrl
5. 5.↵
   1. Grundy SM,
   2. Stone NJ,
   3. Bailey AL,
   4. et al

   . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:3168–209.

   OpenUrlFREE Full Text
6. 6.↵
   1. Grundy SM,
   2. Stone NJ,
   3. Bailey AL,
   4. et al

   . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:e285–e350.

   OpenUrlFREE Full Text
7. 7.↵
   Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention. Cholesterol. Available from: https://www.cdc.gov/cholesterol/. Accessed July 26, 2020.
8. 8.↵
   Healthy People 2020. Heart disease and stroke. Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/heart-disease-and-stroke. Accessed July 26, 2020.
9. 9.↵
   1. Wilson PWF,
   2. Polonsky TS,
   3. Miedema MD,
   4. Khera A,
   5. Kosinski AS,
   6. Kuvin JT

   . Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1144–e1161.

   OpenUrlPubMed
10. 10.↵
    1. Wilson PWF,
    2. Polonsky TS,
    3. Miedema MD,
    4. Khera A,
    5. Kosinski AS,
    6. Kuvin JT

    . Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:3210–27.

    OpenUrlFREE Full Text
11. 11.↵
    1. Ho PM,
    2. Bryson CL,
    3. Rumsfeld JS

    . Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028–35.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Kini V,
    2. Ho PM

    . Interventions to improve medication adherence: a review. JAMA 2018;320:2461–73.

    OpenUrlPubMed
13. 13.↵
    1. Liberman JN,
    2. Hutchins DS,
    3. Popiel RG,
    4. Patel MH,
    5. Jan SA,
    6. Berger JE

    . Determinants of primary nonadherence in asthma-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits 2010;2:111–8.

    OpenUrl
14. 14.↵
    1. Raebel MA,
    2. Ellis JL,
    3. Carroll NM,
    4. et al

    . Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 2012;27:57–64.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Shin J,
    2. McCombs JS,
    3. Sanchez RJ,
    4. Udall M,
    5. Deminski MC,
    6. Cheetham TC

    . Primary nonadherence to medications in an integrated healthcare setting. Am J Manag Care 2012;18:426–34.

    OpenUrlPubMed
16. 16.↵
    1. Tamblyn R,
    2. Eguale T,
    3. Huang A,
    4. Winslade N,
    5. Doran P

    . The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med 2014;160:441–50.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Harrison TN,
    2. Derose SF,
    3. Cheetham TC,
    4. et al

    . Primary nonadherence to statin therapy: patients’ perceptions. Am J Manag Care 2013;19:e133–e139.

    OpenUrlPubMed
18. 18.↵
    1. Cheetham TC,
    2. Niu F,
    3. Green K,
    4. et al

    . Primary nonadherence to statin medications in a managed care organization. J Manag Care Pharm 2013;19:367–73.

    OpenUrlPubMed
19. 19.↵
    1. Derose SF,
    2. Green K,
    3. Marrett E,
    4. et al

    . Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 2013;173:38–43.

    OpenUrl
20. 20.↵
    Surescripts Network Alliance. Available from: https://surescripts.com/. Accessed July 26, 2020.
21. 21.↵
    1. Tarn DM,
    2. Guzman JR,
    3. Good JS,
    4. Wenger NS,
    5. Coulter ID,
    6. Paterniti DA

    . Provider and patient expectations for dietary supplement discussions. J Gen Intern Med 2014;29:1242–9.

    OpenUrl
22. 22.↵
    1. Tarn DM,
    2. Paterniti DA,
    3. Williams BR,
    4. Cipri CS,
    5. Wenger NS

    . Which providers should communicate which critical information about a new medication? Patient, pharmacist, and physician perspectives. J Am Geriatr Soc 2009;57:462–9.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Tarn DM,
    2. Mattimore TJ,
    3. Bell DS,
    4. Kravitz RL,
    5. Wenger NS

    . Provider views about responsibility for medication adherence and content of physician-older patient discussions. J Am Geriatr Soc 2012;60:1019–26.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Tarn DM,
    2. Paterniti DA,
    3. Wenger NS,
    4. Williams BR,
    5. Chewning BA

    . Older patient, physician and pharmacist perspectives about community pharmacists’ roles. Int J Pharm Pract 2012;20:285–93.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Gubrium JF

    . The Sage handbook of interview research: the complexity of the craft. 2nd ed. Thousand Oaks, CA: Sage Publications; 2012.
26. 26.↵
    1. Gubrium JF,
    2. Holstein JA

    . Handbook of interview research: context & method. Thousand Oaks, CA: Sage Publications; 2002.
27. 27.↵
    1. Babbie ER

    . The basics of social research. 6th ed. Belmont, CA: Wadsworth, Cengage Learning; 2014.
28. 28.↵
    1. Denzin NK,
    2. Lincoln YS

    . The Sage handbook of qualitative research. 4th ed. Thousand Oaks, CA: Sage Publications; 2011.
29. 29.↵
    World Health Organization (WHO). Adherence to long-term therapies: evidence for action. 2003. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed July 26, 2020.
30. 30.↵
    1. Elseviers M,
    2. Wettermark B,
    3. Almarsdóttir AB,
    4. et al.

    1. Traulsen J,
    2. Britten NJK

    . Patient perspectives. In: Elseviers M, Wettermark B, Almarsdóttir AB, et al., eds. Drug utilization research. Hoboken, NJ: Wiley-Blackwell; 2016:347–54.
31. 31.↵
    1. Ju A,
    2. Hanson CS,
    3. Banks E,
    4. et al

    . Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract 2018;68:e408–e419.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Polinski JM,
    2. Kesselheim AS,
    3. Frolkis JP,
    4. Wescott P,
    5. Allen-Coleman C,
    6. Fischer MA

    . A matter of trust: patient barriers to primary medication adherence. Health Educ Res 2014;29:755–63.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Tarn DM,
    2. Heritage J,
    3. Paterniti DA,
    4. Hays RD,
    5. Kravitz RL,
    6. Wenger NS

    . Physician communication when prescribing new medications. Arch Intern Med 2006;166:1855–62.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Tarn DM,
    2. Paterniti DA,
    3. Heritage J,
    4. Hays RD,
    5. Kravitz RL,
    6. Wenger NS

    . Physician communication about the cost and acquisition of newly prescribed medications. Am J Manag Care 2006;12:657–64.

    OpenUrlPubMedWeb of Science
35. 35.↵
    1. Navar AM,
    2. Wang TY,
    3. Mi X,
    4. et al

    . Influence of cardiovascular risk communication tools and presentation formats on patient perceptions and preferences. JAMA Cardiol 2018;3:1192–9.

    OpenUrl
36. 36.↵
    1. Morgan DL

    . Focus groups as qualitative research. 2nd ed. Thousand Oaks, CA: Sage Publications; 1997.
37. 37.↵
    Pew Research Center Internet and Technology. Internet use by age. Available from: https://www.pewinternet.org/chart/internet-use-by-age/. Accessed July 26, 2020.